¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-04-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-04-27
±³À°ÀÏÀÚ : 2024-04-27
±³À°Àå¼Ò : º¤½ºÄÚ Á¦2Àü½ÃÀå

±³À°ÁÖÁ¦ : 2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷

ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÀÌÀº¿µ
¿¬¶ôó : 02-512-5915  

À̸ÞÀÏ : gyncancer@gyncancer.or.kr

±³À°Á¾·ù : »êºÎÀΰú

Âü¼®¿¹»óÀÎ : 350¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 11 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 150,000¿ø  

ºñ°í - ºÎÀÎ¾Ï ºÐ°úÀü¹®ÀÇ : 15¸¸ ¿ø- ÀüÀÓÀÇ ¹× ±âŸ ºÐ°ú Àü¹®ÀÇ : 13¸¸ ¿ø- Àü°øÀÇ : 10¸¸ ¿ø- ¿¬±¸¿ø ¹× °£È£»ç : 11¸¸ ¿ø- 65¼¼ ÀÌ»ó : ¹«·á((¸¸Âù 2¸¸¿ø Ãß°¡ / JGO Workshop : ¹«·á)


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 09:00~09:15 Update of hereditary gynecologic cancer guideline ÇÏÇüÀÎ(ºÎ»êÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 09:15~09:20 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 09:20~09:35 Clinical application of BRCA/HRD in the management of ovarian cancer ¾î°æÁø(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 09:35~09:40 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 09:40~09:55 Clinical application of MMR in the management of endometrial cancer ±èÁöÇö(±¹¸³¾Ï¼¾ÅÍ)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 09:55~10:00 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 10:00~10:30 ÀÇÇÐ³í¹®¿¡¼­ »ý¼ºÇü AIÀÇ È°¿ë »ç·Ê À¯½ÂÂù(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í½Ã½ºÅÛÁ¤º¸Çб³½Ç)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 10:30~10:50 Q&A ( )

ÈÞ½Ä 04¿ù 27ÀÏ 11:00~11:20 Break Time ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 11:20~11:35 Advanced/recurrent cervical cancer ¾î°æÁø(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 11:35~11:40 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 11:40~11:55 Advanced/recurrent endometrial cancer ³²¼ÒÇö(¿ï»êÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 11:55~12:00 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 12:00~12:15 Major three A/E: management tips ÀÓÇöÁö(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 12:15~12:20 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 12:20~12:35 Beyond the immune-oncologics in gynecologic cancer ÀÌ¿ëÀç(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 12:35~12:40 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 12:40~13:00 Pembrolizumab in combination with CCRT: the next frontier for LACC ½Å¼ÒÁø(°è¸íÀÇ´ë)

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 13:00~13:20 Clinical benefit of Niraparib as 1L maintenance in newly diagnosed ovarian cancer focused on BRCAmut and HRD ³ëÁØÈ£(¼­¿ïÀÇ´ë)

ÈÞ½Ä 04¿ù 27ÀÏ 13:20~13:50 Break Time ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 13:50~14:20 Experience of Operating the Molecular Tumor Board Jihong Liu(Sun Yat-sen University Cancer Center)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 14:20~14:30 Case presentation Ȳµ¿¿ø(ÀÎÁ¦ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 14:30~14:40 Floor discussion ( )

ÈÞ½Ä 04¿ù 27ÀÏ 14:40~15:00 Break Time ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 15:00~15:20 Interpretation of Endometrial Curettage ±èÇö¼ö(¼º±Õ°üÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 15:20~15:25 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 15:25~15:45 Practical Approach of Molecular Classification in Endometrial Cancer ±èÈ¿Áø(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 15:45~15:50 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 5A Hall 15:50~16:10 2023 Revised FIGO Stage of Endometrial Cacner ¹ÚÀºÇâ(¿¬¼¼ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 5A Hall 16:10~16:15 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 10:00~10:20 ±¹³»¿Ü ÀڱðæºÎ¾Ï °ËÁø ±Ç°í¾È ¼Ò°³ ÀÓö±Ç(À»ÁöÀÇ´ë)

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 10:20~10:40 ±¹³» HPV °Ë»ç ÇöȲ ¹× Á¤µµ °ü¸® ÇöȲ ±èÁÖÇö(¿ï»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 10:40~11:00 HPV °Ë»ç ÀÓ»ó ±Ç°í¾È °èȹ ¹× ±¸¼º ¼Ò°³ ±è¼¼ÀÍ(¼­¿ïÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 11:00~12:00 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 13:20~13:50 Lunch Time ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 13:50~14:02 (ÃʷϹßÇ¥) Video demonstration of vNOTES pelvic lymphadenectomy in gynecologic cancer À̱ÙÈ£(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 321/322/323/324 14:02~14:05 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 14:05~14:12 (ÃʷϹßÇ¥) Metastatic pancreatic carcinoma to the uterine cervix, vNOTES contributed to the diagnosis.£ºA case report. Yu Kamishita(Saga-Ken Medical Centre Koseikan Japan)

Åä·Ð 04¿ù 27ÀÏ 321/322/323/324 14:12~14:15 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 14:15~14:22 (ÃʷϹßÇ¥) Robot assisted laparoscopic surgery in loco-regionally recurrent ovarian cancer ¼Û¹ÎÁ¾(°¡Å縯ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 321/322/323/324 14:22~14:25 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 321/322/323/324 14:25~14:32 (ÃʷϹßÇ¥) Ureteroureterostomy during laparoscopic radical hysterectomy ¹Úö¹Î(Á¦ÁÖÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 321/322/323/324 14:32~14:35 Floor discussion ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 121/122 09:00~09:30 ¼ö¼úµ¿ÀǼ­ ¼Ò°³ (¿ÜÀ½ºÎ¾Ï, ÀÚ±ÃÀýÁ¦¼ú) ÀÌ°Ç¿ì(Ãæ³²ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 121/122 09:30~09:40 Distallate discussion ¿À¼öÇö(°¡ÃµÀÇ´ë)

ÈÞ½Ä 04¿ù 27ÀÏ 09:40~10:00 Break Time ( )

±³À°½Ã°£ 04¿ù 27ÀÏ 121/122 10:00~10:25 ÀڱðæºÎ¾Ï ÀÌÇØÇϱ⠹ڻóÀÏ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø)

±³À°½Ã°£ 04¿ù 27ÀÏ 121/122 10:25~10:50 Àڱ󻸷¾Ï ÀÌÇØÇϱâ Áö¿ëÀÏ(ºÎ»êÀÇ´ë)

±³À°½Ã°£ 04¿ù 27ÀÏ 121/122 10:50~11:15 ³­¼Ò¾Ï ÀÌÇØÇϱ⠼­µ¿¼ö(°í½ÅÀÇ´ë)

±³À°½Ã°£ 04¿ù 27ÀÏ 121/122 11:15~11:40 ºÎÀξϿ¹¹æÇϱ⠺¯Á¤¹Ì(ÀÎÁ¦ÀÇ´ë)

Åä·Ð 04¿ù 27ÀÏ 121/122 11:40~12:00 ÁúÀÇ ¹× Åä·Ð ( )

ÈÞ½Ä 04¿ù 27ÀÏ 12:00~13:50 Break Time ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦39Â÷ Ãá°èÇмú´ëȸ 2ÀÏÂ÷ : 2024-04-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024³â ´ëÇѳ»°úÇÐȸ Ãá°èÇмú´ëȸ : 2024-04-27
´ÙÀ½±Û 2024 Çѱ¹´ç´¢º´¿¹¹æ¿¬±¸(KDPS) Ãá°è ½ÉÆ÷Áö¾ö : 2024-04-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
270 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Á¦53Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2018-09-16 0 576 2018-07-28
269 ¼­¿ï 2018³â Á¦3ȸ »ï¼º¼­¿ïº´¿ø ¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-09-16 0 938 2018-07-28
268 ´ë±¸ 2018³âµµ ´ëÇÑÁ¤Çü¿Ü°úÀÇ»çȸ Çмú´ëȸ : 2018-09-16 0 826 2018-07-28
267 ¼­¿ï ½ÉÀå´ë»çÁõÈıº¿¬±¸È¸ 2018 Ãß°è½ÉÆ÷Áö¾ö : 2018-09-15 0 677 2018-07-28
266 ¼­¿ï °æÈñ´ëÇб³º´¿ø µ¿¹®Áý´ãȸ_°íȲÀ̺ñÀÎÈÄ°ú ¿¬±¸È¸ ¼¼¹Ì³ª : 2018-09-15 0 1,401 2018-07-28
265 ¼­¿ï 2018 Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ Á¤½ÅÄ¡·á Àü¹®°úÁ¤ : °æ°è¼± ÀΰÝÀå¾Ö : 2018-09-15 0 1,177 2018-07-28
264 ¼­¿ï ¼­¿ï¼º¸ðº´¿ø ½ÅÀåÀÌ½Ä 3,000·Ê ±â³ä ´ëÇÑÀ̽ÄÇÐȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2018-09-15 0 619 2018-07-28
263 °­¿ø ´ëÇÑ°ñÀýÇÐȸ Á¦2ȸ ÇÏÁö°ñÀý ½ÉÆ÷Áö¾ö : 2018-09-15 0 577 2018-07-28
262 Àü³² ¸ñÆ÷½ÃÀÇ»çȸ Çмú´ëȸ(°æµ¿¸Æ¼Õ»ó,°áÇÙ) : 2018-09-15 0 2,687 2018-07-28
261 ¼­¿ï °í·Á´ëÇб³ ½Å°æ°úÇб³½Ç ½ÉÆ÷Áö¿ò : 2018-09-15 0 1,940 2018-07-28
260 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø ÄÚºí·¹ÀÌÅ͸¦ ÀÌ¿ëÇÑ ´Ù¾çÇÑ ºñ°ú ¼ö¼úµé : 2018-09-15 0 763 2018-07-28
259 °æ±â Á¦6ȸ ÇѸ²´ëÇб³¼º½Éº´¿ø Á¤Çü¿Ü°ú °³¿øÀÇ ½ÉÆ÷Áö¿ò : 2018-09-15 0 876 2018-07-28
258 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø ¾È°ú ±Ý¿ä¼¼¹Ì³ª : 2018-09-14 0 621 2018-07-28
257 ¼­¿ï »ï¼º¼­¿ïº´¿ø 2018 »ï¼º ¾È°ú ±Ý¿äÁý´ãȸ : 2018-09-14 0 657 2018-07-28
256 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018 ÀÇ·áÇöÀå¿¡¼­ ¸¸³ª´Â ¾à¹°¾Ë·¹¸£±â : 2018-09-14 0 822 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷